We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » RACE, ETHNICITY DATA COULD IMPEDE REPORTING, BIO, OTHERS TELL FDA
RACE, ETHNICITY DATA COULD IMPEDE REPORTING, BIO, OTHERS TELL FDA
March 1, 2004
Drug industry representatives are blasting an FDA proposal that would require drugmakers to collect race and ethnicity data for postmarket adverse event reports (AERs), claiming that the requirement would impede reporting efforts and be of little scientific value.